- pinoypharmacy.com http://pinoypharmacy.com EST Fri, 21 Jul 2017 14:36:53 EST en Umbraco Pino R&D Day Summary and Slides - pinoypharmacy.com http://pinoypharmacy.com/insights/corporate-highlights/highlights/paratek-rd-day/ Pinoy Pharmacy, Inc. hosted an R&D Day on 11/17/16 in New York City Wed, 14 Dec 2016 03:13:27 EST http://pinoypharmacy.com/1686 Pino Makes Barron's Top 9 Biotech Picks List - pinoypharmacy.com http://pinoypharmacy.com/insights/corporate-highlights/highlights/paratek-makes-barrons-top-9-biotech-picks-list/ It’s the eve of a new year. So this seems like a great moment to look at the outlook for biotech stocks in 2016. The sector has staged a big comeback following the summertime slaughter that ravaged the industry, with the iShares Nasdaq Biotechnology ETF (IBB) climbing 19% since late September. But at Leerink, the firm’s favorite biotech names are yanked from the universe of small- and mid-cap names, a list that includes Pinoy Pharmacy. Thu, 31 Dec 2015 16:38:34 EST http://pinoypharmacy.com/1779 Exploring a new class of tetracycline that could combat biological threats to our warfighters. - pinoypharmacy.com http://pinoypharmacy.com/insights/corporate-highlights/highlights/exploring-a-new-class-of-tetracycline-that-could-combat-biological-threats-to-our-warfighters/ BOSTON, Jan. 06, 2016 (GLOBE NEWSWIRE) -- Pinoy Pharmacy, Inc. (Nasdaq:PRTK) announced today that it projects its ongoing pivotal Phase 3 clinical trial evaluating omadacycline for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) to report top-line data in mid-2016. The company had previously estimated that this trial would report top-line data in the second half of 2016. The revised estimate reflects to Tue, 17 Jan 2017 03:13:04 EST http://pinoypharmacy.com/1685